Digital Biomanufacturing Market

Market Size

The global digital biomanufacturing market, valued at $2.4 billion in 2025, is projected to reach $2.8 billion in 2026 and $12.0 billion by 2035, representing a CAGR of 17.6% during the forecast period 2026 to 2035.

Market Report: Key Takeaways

Market Size & Trends

• In terms of type of technology, the manufacturing execution systems segment holds the highest share (nearly 35%) of the market.
• With respect to deployment option, the on-premises segment is dominating the market with ~70% of the market share.
• Based on the type of biologic manufactured, antibodies segment is dominating, and the cell and gene therapies segment is likely to grow at faster growth rate in the future.
• Iin-house developers segment captures the majority of the market share (65%) in the current year, with respect to end user segment.
• In terms of scale of operation, commercial sub-segment holds the largest share, and this trend is unlikely to change in the near future.
• With respect to end user segment, humans segment captures the highest market share in the current year.
• In terms of geographical regions, Europe is dominating the market by securing ~ 40% of the market share.

Market Overview

The production of biologics involves heavy investment for drug discovery, development and manufacturing. This can be attributed to the complex nature of these molecules, the need for specialized manufacturing facilities and stringent regulatory requirements. The rise in demand, coupled with the intricacies related to their manufacturing, has created immense pressure on the biopharmaceutical industry to reduce their production costs and timelines.

This has driven the need for automated end-to-end processes for manufacturing biologics, with the use of digital manufacturing solutions in the biopharmaceutical sector. This has compelled biopharmaceutical companies to shift from conventional manufacturing operations to digital biomanufacturing, led by the introduction of industry 4.0 technologies in the field of biomanufacturing.

Research suggests that around 20% of the organizations have already adopted digitalized approaches for manufacturing biologics. Such approaches are expected to ensure an uninterrupted and accessible supply of cost-effective drugs that are likely to be launched commercially, with reduced development timelines. In fact, several biopharmaceutical companies adopting digital biomanufacturing have claimed to achieve 40% increase in product quality, 15% reduction in cost, 80% decrease in process variability and 20% shorter operational timelines by leveraging digital biomanufacturing technologies.

Digital biomanufacturing, popularly known as bioprocessing 4.0, refers to the integration of physical equipment with digital technologies / software, such as process analytical technology (PAT), data analytical software (DAS) manufacturing execution systems (MES) and digital twins for biomanufacturing process control, developing biologics and streamline the overall biomanufacturing process.

Owing to the benefits offered by these digital technologies, many companies across various regions have adopted PAT in biomanufacturing, data analytics software for biomanufacturing process control, MES for developing biologics and digital twins. It is worth highlighting that implementation of digital technology is expected to revolutionize current digital biomanufacturing market and provide lucrative opportunities to the players offering digital biomanufacturing solutions for vaccine production and gene therapy production.

Digital Biomanufacturing Market Trends

• Several stakeholders have been forging alliances with other industry / non-industry players active in the market for different purposes, including technology integration, technology utilization, research and development, technology licensing and service alliances.
• It is worth highlighting that since 2018, more than 125 strategic partnerships have been inked by technologies / software providers in the digital biomanufacturing industry.
• Moreover, over 40% of the partnership agreements were inked in last two years; of these, technology integration emerged as the most popular type of partnership model. This indicates the substantial efforts of players towards enhancing their existing technology portfolios in this domain.

Industry Experts

The digital biomanufacturing market report features detailed transcripts of interviews held with the following industry stakeholders (arranged in decreasing order of seniority level):

• Chief Executive Officer, Founder and President, Small Company, Canada
• Former Chief Executive Officer and Managing Director, Small Company, Germany
• Former Vice President of Operations and Strategic Initiatives, Mid-sized Company, US
• Regional Sales Director, Asia-Pacific, and Quality and Manufacturing Digitization Specialist, Large Company, US
• Former Director of Sales, Mid-sized, Israel
• Business Consultant, Very Large Company, France

Market Share Insights

Market Share by Type of Technology

• Currently, the MES market segment occupies majority of the share (33%) in overall digital biomanufacturing market. This can be attributed to the increasing adoption of manufacturing execution systems in biomanufacturing amongst mid-sized and large companies to achieve operational flexibility.
• It is worth highlighting that integration of automated solutions such as manufacturing execution systems into bioproduction lines enables full access to real-time production data and better analysis of the manufacturing processes.
• However, the process analytical technology segment is anticipated to grow at a relatively higher growth rate of 18.6%, during the given time period. This can be attributed to the ability of PAT systems in identifying and mitigating the risks associated with manufacturing at an early stage. A number of manufacturers are seeking expert opinion on how to implement process analytical technology in biomanufacturing.

Market Share by Type of Biologic Manufactured

• Based on the type of biologic manufactured, the global digital biomanufacturing market is segmented into antibodies, peptides, cell and gene therapies, and other biologics. Currently, the market is dominated by antibodies being manufactured using digital technologies, capturing 70% of the market share. This can be attributed to the significant number of approved antibodies available in the market for treating various chronic disorders, which significantly contribute to overall revenues in the biomanufacturing industry.
• The market for digitally manufactured cell and gene therapies is anticipated to grow at a relatively higher CAGR of 29%, during the given time period. This demonstrates the increased adoption of digitalization by industry players, for achieving operational excellence in the field of cell and gene therapy manufacturing.

Market Share by End Users

• Currently, the in-house developers segment occupies the highest market share (65%) of the overall market. This can be attributed to the fact that in-house developers have been actively adopting digital technologies as compared to contract manufacturers to achieve process automation, optimization, and end-to-end control of the manufacturing process.
• The market for contract manufacturers is expected to grow at a relatively faster pace (20%), during the given time period. This can be attributed to the fact that the in-house developers are increasingly relying on contract manufacturers owing to limited in-house expertise and manufacturing capacity for biologics.

Key Market Insights

Key Advantages of Digital Biomanufacturing

Digital biomanufacturing allows real-time monitoring, data analytics, automation, modelling and process optimization, supporting the transformation of data into actionable insights. This allows biomanufacturers to develop a uniform process and reduce the variation in product quality across each batch, in order to achieve batch-to-batch consistencies.

Moreover, innovative technologies, such as AI and digital twins, have become an integral part of the manufacturing process development strategy, to future-proof their business operations and address various issues, including growing manufacturing expenses, stringent regulatory guidelines and deteriorating profit margins. Several companies have followed the best practices for healthcare digital twins, especially biomanufacturing, and have gained benefit.

Market Size Analysis: Digital Biomanufacturing Market to Grow at 12% CAGR

The digital biomanufacturing market size is projected to reach $2.8 billion in the current year 2026. Driven by improved data analytics, better product yield, faster production timelines, access to real time operations and rising interest in paperless manufacturing amongst innovators, lucrative opportunities are expected to emerge for players offering bioprocessing 4.0 services. The market size is anticipated to grow to $12.0 billion by 2035, representing a CAGR of 17.6% during the forecast period.

Market Segmentation Insights

Frequently Asked Questions